Laurion Capital Management’s Harvard Bioscience HBIO Stock Holding History

Laurion Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,830	Closed	-$66K	–	534
2022 Q2	$66K	Buy	+1,830	New	+$82.6K	﹤0.01%	409
2016 Q3	–	Sell	-9,487	Closed	-$271K	–	993
2016 Q2	$271K	Buy	+9,487	New	+$302K	﹤0.01%	677

Other funds holding HBIO

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return

Laurion Capital Management's HBIO Position: Q3 2022 in Review

Laurion Capital Management sold out of Harvard Bioscience (HBIO) in Q3 2022, closing a stake of 1,830 shares — an estimated $66K sold.

Laurion Capital Management first reported a position in HBIO in Q2 2016 and held it in 2 quarters. The position peaked at $271K in Q2 2016. 79 funds tracked by Wall St. Rank hold HBIO as of Q3 2022.

Laurion Capital Management reported no remaining Harvard Bioscience position as of Q3 2022 after selling out during the quarter.
Laurion Capital Management sold 1,830 Harvard Bioscience shares in Q3 2022, an estimated $66K.
Laurion Capital Management first reported a position in Harvard Bioscience in Q2 2016 and held it in 2 quarters.
Laurion Capital Management's Harvard Bioscience position peaked at $271K in Q2 2016.
79 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2022.

Based on Laurion Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.